Pressure BioSciences, Inc. Announces Initial Equity Research Coverage by TriPoint Global Research

SOUTH EASTON, Mass., Sept. 22, 2010 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (Nasdaq:PBIO) ("PBI" or the "Company") today announced that TriPoint Global Research ("TriPoint") has initiated coverage on the Company, effective September 21, 2010. TriPoint provides independent investment research and innovative, objective analysis for publicly traded companies.

The 21-page initial research report, written by TriPoint Senior Analyst Denise Resnik, MS., can be obtained directly from TriPoint through their website (

Any opinions, judgments, estimates, or forecasts regarding the Company's historical or predicted performance or operations made by TriPoint are theirs alone and do not represent opinions, judgments, estimates, or forecasts of the Company or its management. The Company does not by its reference to the research prepared by TriPoint imply its endorsement or adoption of or concurrence with such information, conclusions, or recommendations.  

About TriPoint Global Research:

TriPoint Global Research was established to meet the growing need for independent research and innovative, objective analysis in a rapidly changing marketplace. TriPoint Global Research strives to bring a consultative/strategic approach to equity research, using comprehensive industry expertise and extensive relationships to analyze the core components of a company.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a NASDAQ Capital Markets listed company focused on the development and sale of instrumentation and consumables based on a novel, enabling technology platform called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 14 U.S. and 10 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts on the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.

Visit us at our website

CONTACT:  Pressure BioSciences, Inc.
          Investor Contacts:
          Richard T. Schumacher, President & CEO
          R. Wayne Fritzsche, Chairman
          (508) 230-1828